Mirikizumab showed superior maintenance efficacy over most treatments for ulcerative colitis (UC), according to a network ...

Operator Welcome to the Bristol Myers Squibb fourth quarter 2024 earnings conference call. [Operator instructions] Please note this event is being recorded. I would now like to turn the conference ...

An international study published in the New England Journal of Medicine provides hope for chronic lymphocytic leukemia (CLL) ...

Bristol-Myers Squibb (NYSE:BMY) reported its fourth-quarter 2024 earnings, surpassing analyst expectations with an earnings ...

Adjuvant treatment with 160 mg aspirin daily for three years cuts recurrence rates in patients with colorectal cancer.